ProfileGDS5678 / 1421074_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 69% 89% 66% 86% 58% 52% 80% 73% 71% 64% 71% 79% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7703374
GSM967853U87-EV human glioblastoma xenograft - Control 24.2953369
GSM967854U87-EV human glioblastoma xenograft - Control 37.1079989
GSM967855U87-EV human glioblastoma xenograft - Control 44.0168766
GSM967856U87-EV human glioblastoma xenograft - Control 56.5933186
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5739258
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3458752
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6881780
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6827173
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5405871
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7995464
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4560971
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.498579
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8174264